Alterations in cytokine profile and dendritic cells subsets in peripheral blood of rheumatoid Arthritis Patients before and after Biologic Therapy

Annals of the New York Academy of Sciences

Volumn 1173, Issue , 2009, Pages 334-342

  Marti, Luciana ^a   Golmia, Ricardo ^a,c   Golmia, Andrea Pimentel Fonseca ^a,c   Paes, Ângela Tavares ^a   Guilhen, Daiane Donna ^a   Moreira Filho, Carlos Alberto ^b   Scheinberg, Morton ^a,c  

^a HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c Hospital Abreu Sodré   (Brazil)

Author keywords

Arthritis; Cytokines; Dendritic cell; Rheumatoid

Indexed keywords

ABATACEPT; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; VASCULOTROPIN;

ADULT; BIOLOGICAL THERAPY; BLOOD; BONE MARROW CELL; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; FEMALE; HUMAN; IMMUNE RESPONSE; MALE; PLASMA CELL; RHEUMATOID ARTHRITIS;

EID: 69949186313     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.04740.x     Document Type: Conference Paper

References (35)

1. Noss, E.H. & M.B. Brenner. 2008. The role and therapeutic implications of fibroblast-like synoviocytes in inflammation and cartilage erosion in rheumatoid arthritis. Immunol. Rev. 223: 252-270. Review.
2. Wagner, U.G., P.J. Kurtin, A. Wahner, et al. 1998. The role of CD8 +CD40L+ T cells in the formation of germinal centers in rheumatoid synovitis. J. Immunol. 161: 6390-6397.
3. Yanni, G., A. Whelan, C. Feighery & B. Bresnihan. 1994. Synovial tissue macrophages and joint erosion in rheumatoid arthritis. Ann. Rheum. Dis. 53: 39-44.
4. Takakubo, Y., M. Takagi, K. Maeda, et al. 2008. Distribution of myeloid dendritic cells and plasmacytoid dendritic cells in the synovial tissues of rheumatoid arthritis. J. Rheumatol. 35: 1919-1931.
5. Steinman, R.M., D. Hawiger & M.C. Nussenzweig. 2003. Tolerogenic dendritic cells. Annu Rev Immunol. 21: 685-711. Review.
6. Gill, M.A., P. Blanco, E. Arce, et al. 2002. Blood dendritic cells and DC-poietins in systemic lupus erythe-matosus. Hum. Immunol. 63: 1172-1180.
7. Migita, K., T. Miyashita, Y. Maeda, et al. 2005. Reduced blood BDCA-2 +(lymphoid) and CD11c+ (myeloid) dendritic cells in systemic lupus erythe-matosus. Clin. Exp. Immunol. 142: 84-91.
8. Scheinecker, C., B. Zwolfer, M. Koller, et al. 2001. Alterations of dendritic cells in systemic lupus ery-thematosus: phenotypic and functional deficiencies. Arthritis Rheum. 44: 856-865.
9. Dzionek, A., A. Fuchs, P. Schmidt, et al. 2000. BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood. J. Immunol. 165: 6037-6046.
10. Arpinati, M., G. Chirumbolo, B. Urbini, et al. 2003. Role of plasmacytoid dendritic cells in immunity and tolerance after allogeneic hematopoietic stem cell transplantation. Transpl. Immunol. 11: 345-356. Review.
11. Cella, M., D. Jarrossay, F. Facchetti, et al. 1999. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat. Med. 5: 919-923.
12. Siegal, F.P., N. Kadowaki, M. Shodell, et al. 1999. The nature of the principal type 1 interferon-producing cells in human blood. Science 284: 1835-1837.
13. Weaver, C.T., R.D. Hatton, P.R. Mangan & L.E. Harrington. 2007. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu. Rev. Immunol. 25: 821-852. Review.
14. Bettelli, E., T. Korn, M. Oukka & V.K. Kuchroo. 2008. Induction and effector functions of T(H)17 cells. Nature 453: 1051-1057.
15. Bulpitt, K.J. 1999. Biologic therapies in rheumatoid arthritis. Curr. Rheumatol. Rep. 1: 157-163. Review.
16. Fiocco, U., P. Sfriso, F. Oliviero, et al. 2008. Co-stimulatory modulation in rheumatoid arthritis: the role of (CTLA4-Ig) abatacept. Autoimmun. Rev. 8: 76-82.
17. Teng, G.G., A.M. Turkiewicz & L.W. Moreland. 2005. Abatacept: a costimulatory inhibitor for treatment of rheumatoid arthritis. Expert. Opin. Biol. Ther. 5: 1245-1254.
18. Van Der Bijl, A.E., Y.P. Goekoop-Ruiterman, J.K. de Vries-Bouwstra, et al. 2007. Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis. Arthritis Rheum. 56: 2129-2134.
19. Siddiqui, M.A. 2007. The efficacy and tolerability of newer biologics in rheumatoid arthritis: best current evidence. Curr. Opin. Rheumatol. 19: 308-313. Review.
20. Fox, D.A. 2000. Cytokine blockade as a new strategy to treat rheumatoid arthritis: inhibition of tumor necrosis factor. Arch. Intern. Med. 160: 437-444. Review.
21. Bazzani C., M. Filippini, R. Caporali, et al. 2009. Anti-TNFalpha therapy in a cohort of rheumatoid arthritis patients: Clinical outcomes. Autoimmun. Rev. 8: 260-265.
22. Wijdenes, J., E. Racadot & D. Wendling 1994. Interleukin-6 antibodies in rheumatoid arthritis. J. Interferon. Res. 14: 297-298.
23. Choy, E. 2009. RADIATE: more treatment options for patients with an inadequate response to tumor necrosis factor antagonists. Nat. Clin. Pract. Rheumatol. 5: 66-67.
24. Arnett F.C., S.M. Edworthy, D.A. Bloch, et al. 1988. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31: 315-324.
25. Prevoo, M.L., M.A. van't Hof, H.H. Kuper, et al. 1995. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 38: 44-48.
26. Van Der Heijde, D.M., M. van 't Hof, P.L. van Riel & L.B. van de Putte. 1993. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J. Rheumatol. 20: 579-81.
27. Van Der Heijde D.M., M. van 't Hof, P.L. van Riel & L.B. van de Putte. 1993. Validity of single variables and indices to measure disease activity in rheumatoid arthritis. J. Rheumatol. 20: 538-41.
28. Grassi, F., A. Hosmalin, D. Mcllroy, et al. 1999. Depletion in blood CD11c-positive dendritic cells from HIV-infected patients. AIDS 13: 759-766.
29. Smith, N., T. Ding, S. Butt, et al. 2008. The importance of the baseline Disease Activity Score 28 in determining responders and non-responders to anti-TNF in UK clinical practice. Rheumatology (Oxford) 47: 1389-1391.
30. Moreland, L.W. & J.R. Curtis. 2008. Systemic nonar-ticular manifestations of rheumatoid arthritis: focus on inflammatory mechanisms. Semin. Arthritis Rheum. [Epub ahead of print].
31. Arend, W.P. & J-M. Dayer. 1995. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis. Arthritis Rheum. 38: 151-160.
32. Lubberts, E. 2008. IL-17/Th17 targeting: on the road to prevent chronic destructive arthritis? Cytokine 41: 84-91.
33. Chitale, S. & R. Moots. 2008. Abatacept: the first T lymphocyte co-stimulation modulator, for the treatment of rheumatoid arthritis. Expert. Opin. Biol. Ther. 8: 115-122.
34. Gerli, R., O. Bistoni, A. Russano, et al. 2002. In vivo activated T cells in rheumatoid synovitis. Analysis of Th1-and Th2-type cytokine production at clonal level in different stages of disease. Clin. Exp. Immunol. 129: 549-555.
35. Nishimoto, N., N. Miyasaka, K. Yamamoto, et al. 2008. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod. Rheumatol. 19: 12-19.